These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. The scope of mycoplasma contamination within the biopharmaceutical industry. Armstrong SE; Mariano JA; Lundin DJ Biologicals; 2010 Mar; 38(2):211-3. PubMed ID: 20362237 [TBL] [Abstract][Full Text] [Related]
11. Strategy for an abbreviated in-house qualification of a commercially available Rapid Microbiology Method (RMM) for canadian regulatory approval. Chisholm J; Bhatt S; Chaboureau A; Viswanathan S Cytotherapy; 2017 Dec; 19(12):1529-1536. PubMed ID: 29066052 [TBL] [Abstract][Full Text] [Related]
12. Why and how to implement a rapid sterility test. Gressett G; Vanhaecke E; Moldenhauer J PDA J Pharm Sci Technol; 2008; 62(6):429-44. PubMed ID: 19634346 [TBL] [Abstract][Full Text] [Related]
14. Amendments to sterility test requirements for biological products. Final rule. Food and Drug Administration, HHS Fed Regist; 2012 May; 77(86):26162-75. PubMed ID: 22606719 [TBL] [Abstract][Full Text] [Related]
15. Microbial safety of cell based medicinal products--what can we learn from cellular blood components? Montag T; Nicol SB; Schurig U; Heiden M; Huber H; Sanzenbacher R; Flory E; Schwanig M; Schneider CK Clin Chem Lab Med; 2008; 46(7):963-5. PubMed ID: 18624618 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of growth based rapid microbiological methods for sterility testing of vaccines and other biological products. Parveen S; Kaur S; David SA; Kenney JL; McCormick WM; Gupta RK Vaccine; 2011 Oct; 29(45):8012-23. PubMed ID: 21871516 [TBL] [Abstract][Full Text] [Related]
18. Sterility testing of cell therapy products: parallel comparison of automated methods with a CFR-compliant method. Khuu HM; Patel N; Carter CS; Murray PR; Read EJ Transfusion; 2006 Dec; 46(12):2071-82. PubMed ID: 17176318 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of cell substrates for the production of biologicals: Revision of WHO recommendations. Report of the WHO Study Group on Cell Substrates for the Production of Biologicals, 22-23 April 2009, Bethesda, USA. Knezevic I; Stacey G; Petricciani J; Sheets R; Biologicals; 2010 Jan; 38(1):162-9. PubMed ID: 19818645 [TBL] [Abstract][Full Text] [Related]
20. Transmissible spongiform encephalopathies (TSE): minimizing the risk of transmission by biological/biopharmaceutical products: an industry perspective. Kozak RW; Golker CF; Stadler P Dev Biol Stand; 1996; 88():257-64. PubMed ID: 9119148 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]